The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …

Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …

At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

The route to an effective antiviral treatment against SARS-CoV-2 has been marked by
dozens of negative clinical trials, with thousands of patients across the globe enrolled in …

Abstract Background Favipiravir and Molnupiravir, orally available antivirals, have been
reported to exert antiviral activity against SARS-CoV-2. First efficacy data have been recently …

Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …

Information on the efficacy and safety of molnupiravir in daily clinical practice is very scarce.
We aimed to describe the clinical characteristics and outcomes of fully vaccinated patients …

Abstract Background Molnupiravir (MOV, MK-4482, EIDD-2801) is an orally administered
prodrug of N-hydroxycytidine (NHC, EIDD-1931), a nucleoside with broad antiviral activity …